Key Highlights
- CinDome Pharma raises an additional $40M in Series B financing.
- Funds to support Phase 2 envision3D study for deudomperidone.
- Addresses high unmet medical need for gastroparesis treatment.
- Total Series B raise now at $59M.
Source: Business Wire
Notable Quote
- “This increased investment in CinDome extends our important, ongoing development activities and enables readiness for deudomperidone to enter late-stage trials. We are grateful for the continued support and partnership from Perceptive Advisors to advance this high-impact therapeutic and bring a new hope to people impacted by gastroparesis.” – Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma
SoHC's Take
CinDome Pharma’s recent $40 million extension in their Series B financing round is a significant milestone, bringing their total Series B raise to $59 million. This funding surge underscores the critical need for innovative therapies in the field of gastroparesis, a condition affecting millions in the U.S. alone. The investment will notably support the Phase 2 envision3D study of deudomperidone, an engineered formulation aimed at reducing cardiac liability while improving gastric emptying time. The strategic backing from Perceptive Advisors and the broader CinRx infrastructure positions CinDome Pharma for potential success in addressing a long-standing unmet medical need with a novel therapeutic option.
